http://www.esiason.org/article.php Cystic Fibrosis News Feeds en-us http://www.esiason.org/article.php Alabama has joined 39 other states and the District of Columbia in screening all newborns for cystic fibrosis at birth. Screening gets underway this month. http://www.esiason.org/article.php?wh=185 Hydrox Labs has issued a voluntary recall of Cardinal Health labeled alcohol-free mouthwash. The mouthwash has been tested and been found positive for Burkholderia cepacia (B. cepacia). The Centers for Disease Control has confirmed hospital illnesses in one state associated with the use of the affected mouthwash. http://www.esiason.org/article.php?wh=180 The Cystic Fibrosis Foundation praised the passage of two important pieces of legislation. One law protects those with CF from discrimination based on their genetic disease. The other new bill helps diagnose cystic fibrosis at the earliest stages. http://www.esiason.org/article.php?wh=186 Dr. Lewis E. Gibson, a pediatrician and researcher who developed a safe, highly reliable method to test children for cystic fibrosis, and later helped refine treatments for it, died on April 15 in Sturgeon Bay, Wis. He was 80. http://www.esiason.org/article.php?wh=181 The Cystic Fibrosis Foundation praised the U.S. Senate for officially recognizing May as National Cystic Fibrosis Awareness Month and encouraging public awareness and understanding of CF. http://www.esiason.org/article.php?wh=179 Early detection allows doctors to treat disease quickly. Lucky for Southwest Florida, a goal of Dr. Luis Faverio coincided with a new state requirement for newborn disease screening. http://www.esiason.org/article.php?wh=182 The Cystic Fibrosis Foundation today lauded the U.S. House of Representatives for passing legislation to reauthorize the Small Business Innovation Research (SBIR) program. http://www.esiason.org/article.php?wh=183 Illinois and Vermont have joined 37 other states and the District of Columbia in requiring that all newborns be screened for cystic fibrosis at birth. http://www.esiason.org/article.php?wh=167 FoldRx Pharmaceuticals, Inc. (FoldRx) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today that FoldRx will receive up to $22 million over five years to discover and develop new compounds aimed at treating a core defect in cystic fibrosis. http://www.esiason.org/article.php?wh=166 MONTAUK, Long Island, NY— The Boomer Esiason Foundation (BEF) will partner with the Redbone for the sixth annual F.C.A. Montauk Slam, a national celebrity fishing event to raise funds and awareness for cystic fibrosis, at the Montauk Yacht Club Resort and Marina, Sept. 19 – 21. http://www.esiason.org/article.php?wh=165 Gilead Sciences announced that its Phase III AIR-CF1 study of aztreonam lysine for inhalation for the treatment of people with cystic fibrosis who have pulmonary Pseudomonas aeruginosa met its primary efficacy endpoint of change at 28 days. http://www.esiason.org/article.php?wh=164 May is National Cystic Fibrosis Awareness Month. During this time we have the opportunity to bring awareness and hope to people living with cystic fibrosis (CF), along with their families, friends, and the general public. http://www.esiason.org/article.php?wh=163 University of Pennsylvania Medical School researchers have discovered that a bacterial enzyme may play a role in lung damage in cystic-fibrosis patients, a finding that eventually could lead to a new treatment. http://www.esiason.org/article.php?wh=162 Researchers in the United States have developed a mind-blowing new pill, known as PTC124, that could one day treat nearly 2,000 inherited diseases, including muscular dystrophy and cystic fibrosis. Even better yet, scientists believe that this new "superpill" could be available within just three years. http://www.esiason.org/article.php?wh=161 A recent University of Iowa study reveals a new immune defense mechanism in normal airways and may help explain why people with cystic fibrosis (CF) are particularly susceptible to bacterial lung infections. The findings also may point the way to new approaches for treating the disease. http://www.esiason.org/article.php?wh=160 The abstract, titled Pulmozyme (dornase alfa) Use is Associated with a Slower Rate of Lung Function Decline in Patients with Cystic Fibrosis, was presented on November 3, 2006 at the North America Cystic Fibrosis Conference (NACFC) in Denver, Colorado. The author of the study is Dr. Michael Konstan, M.D., Director of LeRoy W. Matthews Cystic Fibrosis Center at Rainbow Babies and Children's Hospital, Cleveland, Ohio. http://www.esiason.org/article.php?wh=158 Predix Pharmaceuticals Announces Expansion of Research Collaboration with Cystic Fibrosis Foundation Therapeutics Predix to Receive $1.5 Million Milestone Payment; Total Potential Value of Agreement Increased to $16 Million http://www.esiason.org/article.php?wh=159 DURHAM, NC - July 27, 2006 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the initiation of a Phase 3 clinical trial to evaluate its drug candidate, denufosol tetrasodium Inhalation Solution, in patients with mild cystic fibrosis (CF) lung disease. http://www.esiason.org/article.php?wh=157 A team led by Johns Hopkins Childrens Center scientists has identified and successfully tamed an overactive protein that plays a key role in cystic fibrosis (CF), a genetic disorder that interferes with the bodys ability to transport chloride in and out of cells. http://www.esiason.org/article.php?wh=156 Abnormal intracellular lipid processing involving apolipoproteins may contribute to fat malabsorption in cystic fibrosis (CF) patients. http://www.esiason.org/article.php?wh=154 The median age of survival for cystic fibrosis (CF) patients has risen to 36.8 years, up from the previous years figure of 35.1 years, according to new data released by the Cystic Fibrosis Foundation. http://www.esiason.org/article.php?wh=155 Getting coverage for healthcare and medications, as well as knowing your legal rights can be an uphill battle for many people with cystic fibrosis (CF). The more information patients and families have at hand the better equipped they will be. Experts from the CF community joined forces on March 28 to present a live Web cast about how patients can best navigate the world of health insurance and legal rights. The Web cast—hosted by the Cystic Fibrosis Foundation and broadcasted from Houston—drew 922 participants. For more information go to http://www.multicastmedia.com/cff.htm http://www.esiason.org/article.php?wh=153 Anaheim, CA - April 6, 2006 -- Mobile Edge, the premiere designer of innovative and stylish notebook computer carrying cases and accessories, is proud to announce its partnership with the Foundation to help raise funds for research and awareness of cystic fibrosis. Today, Mobile Edge introduces the G-Pak, named after Gunnar Esiason, Boomer's son, and will donate 10 percent of the retail sales of the G-Pak to BEF. http://www.esiason.org/article.php?wh=152 Chiron Corp. of Emeryville, Calif., said Monday, April 3, that Swiss drugmaker Novartis AG had increased its bid for the 56% of the company it does not already own from $45 per share in cash to $48 per share, or about $5.4 billion. http://www.esiason.org/article.php?wh=151 After the first failure of gene therapy. It's widely accepted that treatment leading to a cure for the 50,000 cystic fibrosis sufferers worldwide is an unachievable goal. The limited Research and Devlopment efforts are instead directed towards disease modification and symptomatic treatments with ion channel modulators thought to hold some promise for the future. http://www.esiason.org/article.php?wh=150 Description: Researchers are using an innovative, multi-functional sensing tool to investigate adenosine triposphate (ATP) release and its role in cystic fibrosis. The ATP study marks the first application of a novel sensing system developed by the Georgia Institute of Technology. http://www.esiason.org/article.php?wh=149 Inhaled hypertonic saline is safe and effective additional therapy for cystic fibrosis patients. According to a study from Australia, Inhaled hypertonic saline acutely increases mucociliary clearance and, in short-term trials, improves lung function in people with cystic fibrosis. We tested the safety and efficacy of inhaled hypertonic saline in a long-term trial. http://www.esiason.org/article.php?wh=146 Investigators in the United Kingdom, United States and Canada have published new cystic fibrosis data. A study from England has detailed the crystallographic and single-particle analyses of native and nucleotide-bound forms of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. http://www.esiason.org/article.php?wh=147 Tm Bioscience Corporation (TMC), a commercial genetic testing company, announced it has signed an agreement to supply the Montreal Children's Hospital of the McGill University Health Centre, Montreal, Quebec, with Tag-It reagents for use in its cystic fibrosis (CF) testing program. http://www.esiason.org/article.php?wh=144 According to recently published research from France, cationic lipid mediated gene transfer inhibits tumor necrosis factor (TNF)-alpha and interkeukin-4 (IL-4) in cystic fibrosis (CF) tracheal gland cells. http://www.esiason.org/article.php?wh=141 Foresters announces it will continue support of Children's Miracle Network Radiothon program by renewing its long-standing commitment through 2009 and providing $6 million in funding to underwrite the costs of the international program. http://www.esiason.org/article.php?wh=148 Electromed has introduced its next-generation SmartVest Trimline model airway clearance system in the US, with commercial shipments expected to start in April 2006. Prescribed by a physician, the SmartVest is a personal high frequency chest wall oscillation device that enables patients to take charge of their own therapy, without help from family or other caregivers. The SmartVest uses automated chest and back compression (HFCWO) to provide a more consistent treatment experience for the patient. http://www.esiason.org/article.php?wh=143 An Attractive Option for Patients with Cystic Fibrosis, Bronchiectasis, Obstructive Pulmonary Conditions and Other Diseases Presenting Excess Secretions Most people do not think about taking their next breath; it happens as easily and naturally as blinking an eye. But for individuals with cystic fibrosis, bronchiectasis, chronic obstructive pulmonary conditions, or diseases such as multiple sclerosis and muscular dystrophy, the ability to breathe is a life and death matter. http://www.esiason.org/article.php?wh=142 When Chip Hawkins was born, the prognosis for patients with cystic fibrosis was bleak. Most died as children. Hawkins, now 38, shows how far patients with the rare genetic disease have come, experts say, and how their quality of life may improve even more. http://www.esiason.org/article.php?wh=109 Kamia Bainbridge sat in her hospital room Wednesday, thinking of ways to keep busy. A borrowed laptop sat a few feet away, and craft activities were piled on the floor."I play video games when I'm bored," Kamia said, taking the feeding tube cord that snaked out of her left nostril and tucking part of it behind her ear. Boredom has been a problem for the petite 12-year-old since she had a liver and small bowel transplant about two months ago. But the girl with reddishbrown hair and a dimpled smile gets about 30 minutes of game-play each day in her room at the Nebraska Medical Center, thanks in part to donations from the video game community. http://www.esiason.org/article.php?wh=110 Tm Bioscience Corporation (Toronto, Ontario; TSX: TMC), a leader in the commercial genetic testing market, today announced that it ranked Number 60 on the 2005 Deloitte Technology Fast 500, a ranking of the 500 fastest growing technology companies in North America. Rankings are based on percentage revenue growth over five years, from 2000-2004. http://www.esiason.org/article.php?wh=106 Oriel Therapeutics, an emerging inhaled drug delivery company based in Research Triangle Park, announced today that inventions central to its dry powder inhaler technology have been granted a United States Patent (No. US 6,971,383 issue date Dec 6th, 2005) for dry powder inhaler packages, control systems and dispersion methods. http://www.esiason.org/article.php?wh=102 An observation among Australian surfers with cystic fibrosis that they felt better after riding the waves has inspired a promising new treatment for the incurable disease. Respiratory physician Peter Bye combined the experience of his surfer patients at Sydney's Royal Prince Alfred Hospital with his own scientific knowledge to develop a cheap, natural therapy based on inhaled salt water.. http://www.esiason.org/article.php?wh=103 Pharmaxis has reported that a Phase II clinical trial in patients with cystic fibrosis has dosed its first patients. The study is designed to determine the optimal dose of the mucus-clearing agent Bronchitol, and is being conducted in seven hospitals throughout Canada. http://www.esiason.org/article.php?wh=101 Philip Morris (PM) (USA), tobacco firm, is working on a new type of hand inhaler to treat a number of diseases including lungs affected by smoking. The project is titled Aria and it is a result of PM's unsuccessful efforts to invent a safer alternative to cigarettes. http://www.esiason.org/article.php?wh=100 Sept. 19, 2005--For many Americans, the summer backyard barbecue is just training camp for the real thing, tailgating season. Like the stalwarts of the offensive line, veteran tailgaters hone their skills by testing and tweaking recipes throughout the summer to prepare for the opening game. http://www.esiason.org/article.php?wh=99 Bethesda, Md.; September 2, 2005 The Cystic Fibrosis Foundation will make cystic fibrosis (CF) medications available to all patients affected by Hurricane Katrina regardless of their ability to pay, the organization announced today. http://www.esiason.org/article.php?wh=96 M2 PRESSWIRE-AUGUST 30, 2005-US FDA: FDA announces nationwide recall of Medline brand of alcohol-free mouthwash and hygiene kits containing mouthwash because of possible health risk 1994-2005 M2 COMMUNICATIONS LTD http://www.esiason.org/article.php?wh=95 Altus(R) Pharmaceuticals Inc. announced today that it has successfully completed a Phase II clinical trial of TheraCLEC(TM) in cystic fibrosis (CF) patients with malabsorption due to pancreatic insufficiency. Altus' Phase II study is the largest prospective, randomized, double blind trial ever conducted to evaluate the safety and efficacy of enzyme replacement therapy in the treatment of patients with pancreatic insufficiency. TheraCLEC was well tolerated by patients and the trial achieved its primary efficacy endpoint, a statistically significant improvement in fat absorption. Altus, a leader in the development of novel protein therapies to treat chronic gastrointestinal and metabolic diseases, plans to release the full Phase II results in October 2005 at the North American Cystic Fibrosis Conference in Baltimore, MD. http://www.esiason.org/article.php?wh=94 Growth hormone (GH) therapy is safe and effective for adolescent cystic fibrosis (CF) patients.Endocrinologists in the United States conducted a "retrospective evaluation of data from 25 pubertal adolescents (ages 13 years 4 months to 16 years 11 months, Tanner stage III or IV)." http://www.esiason.org/article.php?wh=91 Researchers report new criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis in a recent issue of the European Respiratory Journal. http://esiason.org/article.php?wh=92 According to recent research from Belgium, nasal polyps (NP) in patients with and without cystic fibrosis (CF) reveal a differentiation by innate markers and inflammatory mediators. http://esiason.org/article.php?wh=93 Tm Bioscience Corporation (TMC), a company in the commercial genetic testing market, announced that its Tag-It Cystic Fibrosis (CF) Kit, a multiplexed human disease genotyping test, has been cleared by the U.S. Food and Drug Administration (FDA) as an in vitro device (IVD) for diagnostic use in the U.S. http://esiason.org/article.php?wh=88 Tm Bioscience Corporation (Toronto, Ontario; TSX: TMC), a leader in the commercial genetic testing market, is pleased to announce that its Tag-It(TM) Cystic Fibrosis (CF) Kit is the first multiplexed human disease genotyping test to be cleared by the U.S. Food and Drug Administration (FDA) as an in vitro device (IVD) for diagnostic use in the United States. http://www.esiason.org/article.php?wh=87 The Cystic Fibrosis Foundation has designated May 2005 as National Cystic Fibrosis Awareness Month to place a national spotlight on cystic fibrosis (CF) and the importance of supporting CF research and medical programs. http://www.esiason.org/article.php?wh=86 Drug PTC124 granted fast track designation from the U.S. Food and Drug Administration (FDA) http://www.esiason.org/article.php?wh=84 Genaera Corporation (NASDAQ:GENR) and Cystic Fibrosis Foundation Therapeutics (CFFT) today announced the receipt of regulatory authorization from the Irish Medicines Board to begin a pivotal Phase II clinical trial for the mucoregulator drug, LOMUCIN(TM), in people with cystic fibrosis (CF) http://www.esiason.org/article.php?wh=85 Cystic Fibrosis Foundation Therapeutics and Galapagos Initiate Alliance to Discover Drug Targets 04/18/2005 - Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), and Galapagos have initiated a two-year target discovery alliance. http://www.esiason.org/article.php?wh=80 Gene-corrected stem cells can help patients with cystic fibrosis."Cystic fibrosis (CF), the most prevalent, fatal genetic disorder in the Caucasian population, is caused by mutations of CF transmembrane conductance regulator (CFTR). The mutations of this chloride channel alter the transport of chloride and associated liquid and thereby impair lung defenses. Patients typically succumb to chronic bacterial infections and respiratory failure,"investigators in the United States report. http://www.esiason.org/article.php?wh=82 Predix Pharmaceuticals Holdings Inc., a drug discovery and development company, and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the drug discovery and development affiliate of the Cystic Fibrosis Foundation, announced today that they have signed a research, development and commercialization agreement. The company will receive up to $12.5 million in milestone driven funds over the next three years through a therapeutics development award from CFFT for two programs. http://www.esiason.org/article.php?wh=79 * How is cystic fibrosis best diagnosed in practice? * Which antibiotics should the GP prescribe for chest infections? * What are the metabolic consequences of CF? J STUART ELBORN MD, FRCP Professor of Respiratory Medicine, Queen's University of Belfast, and Consultant Physician, Belfast City Hospital. Professor Elborn is also Chairman of the Research and Medical Advisory Committee of the Cystic Fibrosis Trust. http://www.esiason.org/article.php?wh=77 Nottingham researchers have found a way to treat children with cystic fibrosis (CF), which could reduce their side effects and see more young patients treated at home. Experts at the University of Nottingham organized the largest successful clinical trial in the U.K. looking at cystic fibrosis in an attempt to discover whether a common antibiotic used to treat the condition could be administered just once a day instead of the usual three daily doses. http://www.esiason.org/article.php?wh=86 PTC Therapeutics, Inc., (PTC) announced that the company has been granted fast track designation from the U.S. Food and Drug Administration (FDA) for the development of its novel drug, PTC124, for the treatment of cystic fibrosis (CF). http://www.esiason.org/archive.php Archived Cystic Fibrosis News